Benefits
Reflux and indigestion
One double-blind, randomised, placebo-controlled trial (indexed as phase III) enrolled 200 adults who already had gastroesophageal reflux symptoms and gave GutGard for 28 days, with follow-up to day 35. Quality of life improved significantly compared with placebo (p = 0.014), and heartburn and regurgitation resolved earlier, within about two weeks. That is a properly designed, brand-specific study, but it is the only one so far, and it was done in people with a diagnosed digestive condition. It does not show that GutGard treats reflux disease or that it changes anything for someone without symptoms.
Stomach lining support
This is a laboratory explanation rather than a proven human benefit. Licorice flavonoids have been reported in preclinical work to increase protective mucus, but no such study is cited on this page, and the single human trial that is cited measured reflux symptoms and quality of life, not the stomach lining.
H. pylori balance
No study cited on this page tested GutGard against H. pylori. Research on licorice extracts and this bacterium exists but is not referenced here, and H. pylori infection is a medical diagnosis that requires testing and prescription treatment from a doctor, not a supplement.
Mechanism of action
Mucosal protection
Licorice flavonoids are thought to increase protective mucus and support the lining of the stomach and esophagus. This is a proposed explanation drawn from laboratory research; it was not measured in the human trial cited on this page.
Glycyrrhizin removed
Ordinary licorice root can raise blood pressure and lower potassium because of a compound called glycyrrhizin. GutGard is standardised to be largely free of glycyrrhizin, which is exactly why that risk is much lower with this form. The flavonoids left behind are the part being studied for digestion, though only one human trial has tested them.
Clinical trials
Double-blind, randomised, placebo-controlled trial (indexed as phase III) of GutGard for gastroesophageal reflux-related symptoms. 296 people screened, 200 enrolled, 28 days of treatment with follow-up to day 35. (Raj et al. 2025, Complementary Medicine Research)
200 adults who already had gastroesophageal reflux symptoms, a diagnosed digestive condition. The findings apply to that group, not to people without symptoms.
Quality of life improved significantly compared with placebo (p = 0.014), and heartburn and regurgitation resolved earlier, within about two weeks. Safety was reported as good. This is a single trial, so the result still needs independent replication, and it does not show that GutGard treats or cures reflux disease.